verubecestat

Known as: N-(3-(3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
02420162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2018
2018
The development of a commercial manufacturing route to verubecestat (MK-8931) is described, highlights of which include the… (More)
Is this relevant?
2018
2018
Verubecestat is an inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) being evaluated in clinical trials for… (More)
Is this relevant?
2018
2018
Alzheimer disease (AD) is a cruel neurodegenerative disorder caused by the deposition of amyloid β (Aβ) peptide inside the brain… (More)
Is this relevant?
2017
2017
Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
2017
Review
2017
Summary: The Food and Drug Administration’s (FDA) approach to approving new medicines for Alzheimer’s disease since the 1990s has… (More)
Is this relevant?
2016
2016
β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer’s disease (AD). The aspartyl protease… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 7
Is this relevant?
2016
2016
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity… (More)
Is this relevant?
2016
2016
Verubecestat is an inhibitor of β-secretase being evaluated for the treatment of Alzheimer's disease. The first-generation route… (More)
Is this relevant?
Review
2016
Review
2016
INTRODUCTION Currently available drugs against Alzheimer's disease (AD) target cholinergic and glutamatergic neurotransmissions… (More)
Is this relevant?